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Abstract
The linkage of vascular genes to specific functions will
lead to a better understanding of cardiovascular patho-
physiology. We developed an experimental model that
enables the introduction of one or multiple gene(s) into
vascular smooth muscle cells (VSMCs) of isolated resis-
tance arteries. Exposure of the arteries to a green fluo-
rescent protein (GFP)-encoding plasmid in combination
with the transfectant Effectene® for 20 h resulted in the
expression of GFP in virtually all VSMCs in the arterial
wall at fully preserved vascular function. For functional
validation of the model, plasmids encoding the specific
RhoA inhibitors C3 transferase or N19RhoA were trans-
fected. In subsequent functional tests, inhibition of
RhoA-dependent constriction induced by sphingosine-1-
phosphate was similar to that in arteries treated with
exogenous C3 transferase protein or the Rho kinase
inhibitor Y27632. Responses to norepinephrine re-
mained unaffected. This novel transfection technique en-
ables gene function to be assessed in direct conjunction
with signalling pathways in vascular tissue and provides,
therefore, a new tool for microvascular proteomics.
Copyright © 2003 S. Karger AG, Basel
Introduction
Recent studies have shed a new light on how variations
in expression patterns of single genes can affect vascular
function [1]. To better characterize functional effects of
distinct genes and their protein products on the cellular
level, overexpression, knockout or targeted mutation of
the respective gene are valuable tools. All of these tech-
niques require effective and reliable introduction of bare-
ly membrane-permeable DNA into cells in culture or
intact tissue. Currently used methods to introduce DNA
plasmids into target cells comprise calcium-phosphate
precipitation, electroporation, detergent-DNA com-
plexes, microinjections as well as virus- and lipid-me-
diated transfection. Poorly differentiated tumor-derived
cell lines have become the main model for gene expression
studies in mammalian cells because in these cells relative-
ly high transfection efficiencies can be achieved. In pri-
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mary cell cultures, however, the uptake of plasmid DNA
is usually low and varies considerably between experi-
ments [2], no matter which non-viral transfection method
was applied. This holds especially true for vascular
smooth muscle cells (VSMC) [3–5] that play a key role in
the regulation of vascular tone and in the development of
atherosclerosis or hypertension. Recent approaches to
transfect VSMCs in culture [6] or intact arterial beds in
vivo [7] were primarily based on adenoviral vectors.
However, viral strategies bear several disadvantages.
They are costly due to their high demands on laboratory
equipment and laboratory safety. Furthermore, their use
as a tool for basic research, especially under in vivo condi-
tions, is compromised by a variety of undesired and bare-
ly controllable effects within the targeted organ or ectopic
tissue [7]. Edema formation, for example, and immuno-
logic responses [8] of intact arteries in vivo at the site of
virus replication seriously reduce their value as an object
for functional studies after explantation.
The aim of the present study was, therefore, to estab-
lish a non-viral experimental model that facilitates highly
efficient transient transfection of VSMCs in isolated func-
tionally intact resistance arteries that, in contrast to cul-
tured cells, enable direct assessment of vascular functions.
Combining a special artery culture protocol [9] with pro-
longed exposure to an optimized mixture of green fluores-
cent protein (GFP)-coding plasmid DNA and the non-
liposomal lipid transfection reagent Effectene®, homoge-
nous expression of GFP throughout the smooth muscle
layers of the vessel wall was achieved. Moreover, transfec-
tion with plasmids coding for RhoA-inhibiting bacterial
C3 transferase or the dominant negative RhoA mutant
N19RhoA completely inhibited sphingosine-1-phosphate
(S1P)-induced, RhoA-mediated constrictions, indicating
functionally relevant gene expression in VSMCs of these
resistance arteries.
This new technology, which enables sufficient VSMC
transfection and subsequent functional studies, combines
advantages of classical approaches in the field of vascular
biology and recent advances in transfection technologies
and provides a new tool for microvascular proteomics.
Methods
Drugs
The MOPS-buffered salt solution used in organ bath experiments
contained (in mmol/l): 145 NaCl, 4.7 KCl, 1.5 CaCl2, 1.17 MgSO4,
1.2 NaH2PO4, 2.0 pyruvate, 0.02 EDTA, 3.0 MOPS and 5.0 glucose.
L15 medium, Cool Calf® serum, norepinephrine (NE) and acetylcho-
line (ACh) were purchased from Sigma (Deisenhofen, Germany),
S1P from Biomol (Hamburg, Germany), Fura-2AM from Molecular
Probes (Oregon, USA) and MnCl2 from Merck (Darmstadt, Germa-
ny). Y27632 [((+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl))] was
kindly provided by Welfide, Osaka, Japan. The plasmid containing
the gene for bacterial C3 transferase [10] was kindly provided by Dr.
Richard Treisman, Imperial Cancer Research Fund Laboratories,
London, UK. The dominant-negative RhoA mutant N19RhoA [11]
was a kind gift from Dr. Alan Hall, University College London, UK.
The promoter-free pGL2 luciferase reporter vector was purchased
from Promega (Mannheim, Germany). The transfectant Effectene
was purchased from Qiagen, Hilden, Germany, Trans-LT was from
Mobitec (Göttingen, Germany).
Concentrations given in the text refer to final bath concentra-
tions.
Preparation of Small Resistance Arteries and Resistance Artery
Culture
The preparation of the arteries, the technique of calcium and
diameter measurements [12] as well as the artery culture method
have been described in more detail previously [9]. Briefly, segments
of small resistance arteries (maximal outer diameter 205–220 Ìm)
were excised from the gracilis muscle of hamsters and cannulated
with glass micropipettes in a culture setup. The segments were per-
fused with culture medium at a rate calculated to apply a physio-
logical constant wall shear stress within the range between 15 and
20 N/m2 to the luminal surface of segments at a transmural pressure
of 45 mm Hg.
Transfection of DNA Plasmids into VSMCs of Intact Resistance
Arteries
For selective transfection of VSMCs by adventitial incubation,
the standard culture medium in the organ bath was replaced by 4 ml
L15 medium containing 15% heat-inactivated Cool Calf serum (pH
7.4), 20,000 U/l penicillin and 20 mg/l streptomycin, 16 Ìl/ml Effec-
tene and 5 Ìg of the respective DNA plasmid [pEFmyc containing
inserts coding GFP (1,045 bp), bacterial C3 transferase (780 bp) or
N19RhoA]. The resistance arteries were incubated at room tempera-
ture (28 °C) for 19–21 h, then washed and incubated with the Ca2+
indicator Fura-2.
Exposure to the transfection solution was limited to 19–21 h
because pilot experiments revealed optimal preservation of vascular
functions for cytomegalovirus (CMV) promoter-driven plasmids for
this time frame.
Determination of Transfection Efficiency, Functional Tests and
Experimental Protocol
At the end of the transfection period, the resistance arteries were
washed with MOPS buffer, placed on the stage of an inverted micro-
scope, warmed up to 37°C, and, after a further incubation period of
2 h with the calcium dye Fura-2, stimulated with the vasoconstrictor
NE (0.3 Ìmol/l) and the endothelium-dependent vasodilator ACh
(1 Ìmol/l). Simultaneous measurements of VSMC intracellular Ca2+,
[Ca2+]i, and of the diameter during exposure to NE and ACh were
performed as previously described [12] to ensure functional intact-
ness of the arteries (data not shown). Only arteries that developed
spontaneous tone (15% with 8–12% considered to be normal in this
type of arteries [12, 13]) were used to study functional parameters (38
of 40 vessels). Arteries transfected with GFP-containing plasmid (n =
8) were studied using confocal laser scanning microscopy to deter-
mine the presence and distribution of GFP-related fluorescence (ex-
Transfection of VSMCs in Intact Resistance
Arteries
J Vasc Res 2003;40:399–405 401
Fig. 1. Serial confocal scans of the microvas-
cular wall. Scans (excitation at 488 nm, em-
ission at 535 nm, pinhole 20) were started at
the subendothelial layer of VSMCs (a) and
continued stepwise (1.5 Ìm) to the VSMC
layer that borders to the adventitial surface
of the resistance artery (b–f). All pictures
shown are representative for 5–8 indepen-
dent experiments.
citation at 488 nm, emission at 535 nm) within the vascular wall. In
order to quantify the transfection efficiency, cell nuclei within the
wall of GFP-transfected arteries were selectively stained with propid-
ium iodide (fig. 2g). Subsequently, every stained nucleus was ana-
lyzed to determine whether the perinuclear cytosol showed GFP-
related fluorescence. Transfection efficiency (%) was calculated as
nGFP-related cytosolic fluorescence/nstained nuclei) W100. Furthermore, vascular
responses of GFP-transfected arteries were compared to those pub-
lished by us for freshly isolated [12] and for cultured resistance arter-
ies (48 h [9]).
Possible cytotoxic effects of the transfectant Effectene were stud-
ied in arteries incubated with this transfectant and a non-replicating
plasmid (pGL2).
To study the efficiency of transfections with the C3-transferase or
N19RhoA plasmids, transfected arteries were tested for their con-
tractile response to the RhoA activator S1P (0.003–3 Ìmol/l). The
results were compared to those obtained in S1P (0.003–3 Ìmol/l)-
stimulated arteries that were incubated with exogenous bacterial C3
transferase protein [incubation for 15–17 h with L15 culture medium
containing antibiotics, the transfectant Trans LT (20 ml/ml) and C3
transferase protein (20 mg/ml, 16 h) or the Rho kinase inhibitor
Y27632 (1 Ìmol/l, 10 min)]. GFP-overexpressing arteries were used
as controls and repeatedly stimulated with S1P (cumulative dose-
response curves, 0.003–3 Ìmol/l) to control time- and transfection-
dependent unspecific effects.
Statistical Analysis
Constriction levels after exposure to NE or S1P are expressed as
‘percent of maximal diameter’ = ((diamax – diavc)/diamax) ! 100, with
diavc representing the steady state outer diameter 2 min after stimu-
lation with the respective dose of the vasoconstricting stimulus and
diamax being the maximal diameter obtained in Ca2+-free MOPS
buffer containing 1 mmol/l EGTA. Measurements were performed at
a transmural pressure of 45 mm Hg.
Steady state values from different groups were compared using
ANOVA followed by post hoc analysis of the means. Data are pre-
sented as means B SEM of n experiments, with n representing the
number of vessels used per experimental series. Differences were
considered significant at an error probability of p ! 0.05.
Curves were compared using a non-linear regression analysis
applied first to every individual curve and then to the pooled data.
Curves were considered to be different if the F-test indicated a signif-
icantly smaller sum of squares for the deviations in each individual
fit as compared to the deviation in the fit to the pooled data [14].
Results
GFP-Related Fluorescence within the Vascular Wall
As determined by means of confocal microscopy, the
vessel wall of third-order skeletal muscle resistance arter-
ies contained three to four layers of VSMCs. The back-
ground fluorescence of untransfected arteries upon excita-
tion at 488 nm was weak and as suggested by figure 1a
most likely emitted by matrix components. VSMCs in
resistance arteries that were adventitially exposed to incu-
bation solution containing the GFP plasmid for 19–21 h
showed GFP-related fluorescence in virtually all VSMCs/
microscopic field (confocal plane) throughout all smooth
muscle layers (fig. 1a–f, 2a–c). A quantification of the
transfection efficiency was performed in 35 confocal
images from five arteries, where 96.5 B 1% of all VSMCs
that showed a propidium-iodide-stained nucleus also re-
vealed GFP-related fluorescence within the cytosol.
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Fig. 2. Expression of GFP in smooth muscle cells of hamster resistance arteries (b–e). Arteries were exposed to a
transfection solution containing a plasmid coding for GFP and confocally scanned after transfection periods for
19–21 h. Non-transfected smooth muscle cells were not fluorescent (a), whereas transfected arteries showed homo-
genous GFP fluorescence confined to the cytosol of smooth muscle cells and absent in the intercellular space.
b Overview. c !3.4. d A 3D projection rebuilt from 51 single confocal slices. Continuous excitation of a selected
region (dotted square) of the vessel at 488 nm induced photobleaching (e). f Deformed VSMCs after a 25-hour
transfection period. g Propidium-iodide-stained cell nuclei in GFP-expressing VSMCs. This protocol was used to
quantify the transfection efficiency. Pictures are representative for 5–8 independent experiments.
After adventitial incubation, no GFP-related fluores-
cence was detectable within the endothelium. The fluores-
cence in VSMCs was strictly intracellular; even at higher
magnification no fluorescence was found within the extra-
cellular space (fig. 2d). Continuous excitation at 488 nm
resulted in bleaching of the GFP-related fluorescence
(fig. 2e) but did not further reduce the background fluo-
rescence emitted by matrix components, for example.
Functional characterization of GFP-transfected arteries
revealed intact contractile responses to 0.3 Ìmol/l NE (46
B 3%, n = 8, vs. 43 B 5% in freshly isolated and 42 B 4%
in cultured resistance arteries [9]) and increases in trans-
mural pressure (from 45 to 110 mm Hg, Bayliss effect).
The latter myogenic responses reversed pressure-induced
distensions of GFP-overexpressing resistance arteries by
55 B 7% (n = 8) within 8 min and were, therefore, not
significantly different from those seen in untransfected
arteries (49 B 14% in freshly isolated and 51 B 16% in
cultured resistance arteries [9]) that were tested in earlier
studies using the same experimental protocol. All arteries
transfected with GFP dilated completely upon stimula-
tion with 1 Ìmol/l of the endothelium-dependent vasodi-
lator ACh (n = 8), indicating that the transfection did not
alter endothelial function.
In vessels that were transfected with the CMV-promot-
er-driven GFP-containing plasmid for 24 h or longer, con-
tractile responses to NE, potassium and pressure as well as
dilations following ACh were abolished (n = 5). Confocal
scans at these time points revealed prominent changes in
cell shape (fig. 2f).
To exclude cytotoxic effects of the transfectant Effec-
tene, being potentially responsible for the loss of function,
arteries were exposed to a mixture of Effectene and a non-
replicating plasmid (pGL2) for 25–27 h. Resting tone (9
B 2%), constrictions to 0.3 Ìmol/l NE (48 B 4%), myo-
genic responses (60 B 12%) and dilations to 1 Ìmol/l ACh
(84 B 7%) in these arteries (n = 4) were not different from
those in freshly isolated [12], cultured [9] or GFP-trans-
fected (19–21 h) arteries.
S1P-Induced Constrictions in Transfected Arteries
S1P (0.003, 0.03, 0.3 and 3 Ìmol) induced dose-depen-
dent constrictions of GFP-transfected resistance arteries
(0.2 B 0.3, 8 B 2, 27 B 3, 45 B 2%, n = 8) that were
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completely reversible after washout and not altered after
repetitive stimulation. Constrictions in response to 0.003,
0.03 and 0.3 Ìmol/l were strictly dependent on RhoA and
Rho kinase, since they were abolished by the exogenously
applied RhoA-inhibiting bacterial toxin C3 transferase
(0.7 B 0.3, 0.5 B 0.6, 2.8 B 0.7%, n = 7, p ! 0.05; fig. 3)
as well as the Rho kinase inhibitor Y27632 (0.1 B 0.4, 0.4
B 0.3, 3.4 B 2%, n = 7, p ! 0.05, fig. 3). Constrictory
responses to 3 Ìmol/l S1P were significantly reduced (18
B 3 and 20 B 7%, respectively, each n = 7, p ! 0.05) but
not completely inhibited by either inhibitor.
Genetic inhibition of RhoA in VSMCs with plasmids
coding for C3 transferase or N19RhoA blocked constric-
tions induced by 0.003, 0.03 and 0.3 Ìmol/l S1P (C3
transferase plasmid: 1 B 0.4, 2 B 1, 4 B 2%, n = 7; p !
0.05; N19RhoA plasmid: 2 B 1, 3 B 2, 6 B 2%, n = 4, p !
0.05; both fig. 3).
As shown with the conventional methods to inhibit
RhoA/Rho kinase, exogenous C3 transferase and
Y27632, although constrictions in response to 3 Ìmol/l
S1P were significantly reduced (to 21 B 5%, n = 7, p !
0.05 for the C3 transferase-containing plasmid and to 18
B 3%, n = 4, p ! 0.05 for the N19RhoA plasmid), they
were not completely inhibited (fig. 3).
In comparison to GFP-overexpressing arteries, neither
transfection with C3 transferase nor with N19RhoA did
significantly reduce resting tone (C3 transferase plasmid:
7 B 3%, n = 7; N19RhoA plasmid: 6 B 3%, n = 4) or
constrictions induced by 0.3 Ìmol/l NE (C3 transferase
plasmid: 48 B 5%; N19RhoA plasmid: 52 B 4%).
Discussion
This study describes a novel transfection model that
enables highly efficient non-viral transfection of VSMC
with DNA plasmids in an intact arterial preparation.
Functional tests after transfection with a plasmid coding
for the heterogenic jellyfish GFP, which should not inter-
fere with the regulation of vascular functions, revealed
that the transfection procedure per se did not affect vascu-
lar responses to vasoconstricting or dilating stimuli.
In contrast, overexpression of two proteins with
known RhoA-inhibiting properties (C3 transferase and
N19RhoA) abolished S1P-induced constrictions, suggest-
ing that the latter are mediated by RhoA and that the
expression level of the transfected proteins was sufficient
to interfere in a highly specific manner with the S1P sig-
nalling pathway in VSMCs of these arteries.
Fig. 3. S1P (0.003–0.3 Ìmol/l)-induced, RhoA-mediated constric-
tions of resistance arteries (control) were abolished after transfection
of plasmids coding for bacterial C3 transferase (n = 7) or the domi-
nant negative RhoA mutant N19RhoA (n = 4). The gene products of
these plasmids had virtually identical effects on S1P-induced con-
striction as exogenous C3 transferase (n = 7) or Y27632 (n = 7),
respectively. Means B SEM; * p ! 0.05 vs. C3 or N19RhoA plasmid-
transfected arteries.
This new model is the first to provide a tool for suffi-
cient non-viral genetic manipulation of VSMCs in intact
isolated resistance arteries to immediately assess func-
tional changes evoked by the protein product of the trans-
fected gene.
VSMCs in non-transfected arteries emitted only weak
background fluorescence upon excitation with 488 nm.
Nineteen to 21 h after transfection with a GFP-coding
plasmid, expression of GFP could be determined based
on its characteristic fluorescence in virtually all VSMCs of
the vascular wall. In contrast to matrix-related autofluo-
rescence, cytosolic fluorescence was sensitive to photo-
bleaching by continuous excitation at 488 nm, further
supporting the assumption that the cytosolic fluorescence
that is not present in untransfected arteries was related to
the alien protein GFP. Not only outer but also subendo-
thelial layers of VSMC of the vascular wall showed GFP-
related fluorescence, indicating sufficient penetration of
the plasmid/transfection reagent mixture. However, the
basal membrane between VSMC and endothelial cells
seems to provide a tight barrier because none of the endo-
thelial cells expressed GFP. This is in agreement with an
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earlier study from our group where FITC-labeled anti-
sense oligonucleotides against cytochrome P450 2C8 were
transfected from the luminal side and remained confined
to the endothelium [13].
The small GTPase RhoA in smooth muscle cells of
these small arteries was genetically inhibited using plas-
mids coding for bacterial C3 transferase or for the domi-
nant negative RhoA mutant N19RhoA. The inhibition of
S1P-induced and RhoA-mediated constrictions by both
constructs was virtually the same as that seen with exoge-
nously administered C3 transferase or Y27632. The inhi-
bition of S1P-induced contractile responses resulting
from transcription of C3 transferase- or N19RhoA-encod-
ing plasmids, respectively, was homogenous along the
cannulated resistance artery. Since N19RhoA and C3
transferase (molecular weights between 21 and 25 kD) are
too large to cross gap junctions and results from dye trans-
fer experiments suggest that VSMC within the vascular
wall of this resistance artery model are barely coupled
[Bolz et al., unpubl. data], a homogenous inactivation of
RhoA requires expression of C3 or N19RhoA in all
VSMC. Contractile responses to a submaximal dose of the
· agonist NE remained unaffected in C3 transferase- or
N19RhoA-transfected arteries. This is in accordance with
a recent paper [15] demonstrating that the · agonist phen-
ylephrine did not affect the activity of the smooth muscle
myosin light chain phosphatase which is the effector pro-
tein for the RhoA/Rho kinase pathway in VSMC. In the
context of the present study, the unaffected responses to
NE in C3 transferase or N19RhoA-overexpressing arter-
ies underline the specificity of the genetic inhibition of
RhoA.
The results presented here suggest that genetic con-
structs coding for either a bacterial inhibitory toxin or an
inhibitory mutant of the targeted protein could replace
chemical inhibitors for microvascular research. There-
fore, the use of genetic inhibitors according to the protocol
presented here provides a promising strategy to overcome
the lack of specificity of chemical inhibitors that often
compromise the results obtained.
In the transfection experiments presented in this study
with both plasmids being driven by a CMV promoter, the
transfection period was kept between 19 and maximally
21 h in order to obtain optimal functional results. The
reason for the decline in vascular reactivity after transfec-
tion periods that exceeded the indicated time frame could
be that the transcription of plasmids is driven by strong
viral promoters, in this case from CMV. These viral pro-
moters recruit large parts of the protein biosynthesis
apparatus of the transfected host cell to produce high
amounts of plasmid-encoded alien protein in short time.
Due to its viral nature, this promotor cannot be regulated
by the host cell. To share limited cellular resources, the
permanently necessary regeneration of cellular proteins
has to slow down, resulting in a net loss of structural and
functional cellular proteins like actin and myosin, and
could be the reason for the complete loss of contractility
along with cell deformation found in arteries after trans-
fection periods exceeding 24 h. As a consequence, it will
be necessary to adjust the transfection protocol to the
strength of each particular viral promoter used by ‘titrat-
ing’ the optimal transfection time. The protocol used in
this study was optimized for the CMV promoter.
Cytotoxic effects of the transfectant Effectene per se
could be ruled out as a cause for the loss of vascular func-
tion because even prolonged exposure (up to 27 h) to a
mixture of Effectene and a non-replicating plasmid did
not affect vascular responses.
In summary, this study introduces a novel model for
the assessment of functional properties of vascular rele-
vant genes in intact isolated resistance arteries. It pro-
vides a new tool to explore the genetic background of
microvascular physiology, most likely resulting in the
identification and characterization of new targets for
innovative therapeutic strategies.
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